European Union member states have dealt Bayer a regulatory blow, rejecting a European Commission proposal that would have allowed numerous crop-protection products to be approved without fixed expiry dates. The decision, reported Thursday, sent the German group’s shares down 5.1% to close at EUR 45.31.
Under the plan, only low-risk active substances would have been exempted from the existing cycle of periodic re-approvals. By voting it down, member states have ensured that manufacturers of plant-protection chemicals will continue to face recurring testing requirements and repeated authorisation procedures. Because agricultural chemicals remain one of Bayer’s core pillars, traders reacted immediately to the prospect of continued strict European approval rules.
A Difficult Backdrop
The Brussels vote landed during an already testing stretch for the Leverkusen-based company. Bayer remains entangled in US litigation over its glyphosate-based weedkiller, with three plaintiffs alleging that exposure to the herbicide caused non-Hodgkin lymphoma. The claimants also assert an alleged product-design defect. Those proceedings have shadowed the group since it acquired US rival Monsanto, and each new case tends to prompt caution among investors.
A fresh courtroom battle unfolded this week in Missouri, where plaintiffs once again challenged the safety and design of the Roundup product line while a verdict was pending. The persistent legal overhang has weighed on sentiment, muting the impact of the company’s operational progress.
JPMorgan Cools Quarter Expectations
Adding to the downbeat mood, JPMorgan analyst Richard Vosser flagged that early consensus estimates for Bayer’s third quarter are likely too optimistic. Investors will get concrete operating figures in a matter of weeks: the group has scheduled publication of its Q3 2026 results for 3 November. Despite the recent pullback, the stock is still up 22% since the start of the year.
Green Milestone in Spain
Away from the courtroom and the regulatory arena, Bayer is pressing ahead with the sustainable overhaul of its manufacturing base. The company received an award this week under the Convive prizes run by utility Iberdrola, recognising the decarbonisation of active-ingredient production for its Aspirin painkiller at the Langreo site in Spain.
Should investors sell immediately? Or is it worth buying Bayer?
Bayer is investing EUR 17 million in the Asturian facility. The new energy system is entering test operation and is slated to move into regular service before the end of 2026. According to the company, the plant will become the first fully decarbonised pharmaceutical production site in Spain, cutting more than 6,500 tonnes of carbon dioxide annually. Process-related emissions from manufacturing the long-established medicine will fall to nearly zero. Bayer regards the factory as one of the first decarbonised production facilities in the pharmaceutical industry anywhere in Europe, a project intended to keep the site competitive over the long term and to prepare it for tougher environmental standards.
Consumer Health and External Innovation
Beyond its European modernisation work, Bayer is pushing ahead in over-the-counter medicines. In the United States it launched MiraSOFT, a stool softener based on the active ingredient docusate sodium. The product is sold exclusively through the CVS Pharmacy chain, available in more than 7,000 stores and via the retailer’s online channel.
Management is also hunting for fresh momentum in its own drug development. Under a showcase run by the Bayer Co.Lab initiative, Asian biotech companies presented their RNA technologies at a specialist conference in Boston. Representatives from Bayer’s business development and licensing units were on hand to explore possibilities for joint projects and partnerships.
Pharma Leadership Change
Alongside the agricultural developments, Bayer announced a personnel move in its pharmaceutical division. Effective 1 October 2026, Dr. Christoph Koenen has been appointed Chief Medical Officer. He takes charge of the division’s medical and scientific strategies, a role he will hold in addition to his existing responsibilities.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from October 2 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 2.
Bayer: Buy or sell? Read more here...
